These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34643782)

  • 21. Transarterial Chemoembolization of HCC with Radiopaque Microspheres: Evaluation with Computed Tomography and the Complementary Role of Contrast-Enhanced Ultrasonography.
    Moschouris H; Malagari K; Dimakis A; Kiakidis T; Anagnostopoulou A
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):1075-1083. PubMed ID: 32394087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multi-arterial phase MRI depicts inconsistent arterial phase hyperenhancement (APHE) subtypes in liver observations of patients at risk for hepatocellular carcinoma.
    Cunha GM; Hasenstab KA; Delgado T; Ichikawa S; Lee MH; Dautt Medina PM; Kim SJ; Lee YH; Kwon H; Sirlin CB; Fowler KJ
    Eur Radiol; 2021 Oct; 31(10):7594-7604. PubMed ID: 33876298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS.
    Bansal S; Lu F; Frehlich L; Wong JK; Burak KW; Wilson SR
    Abdom Radiol (NY); 2022 Feb; 47(2):618-629. PubMed ID: 34800161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LI-RADS-CEUS - Proposal for a Contrast-Enhanced Ultrasound Algorithm for the Diagnosis of Hepatocellular Carcinoma in High-Risk Populations.
    Schellhaas B; Wildner D; Pfeifer L; Goertz RS; Hagel A; Neurath MF; Strobel D
    Ultraschall Med; 2016 Dec; 37(6):627-634. PubMed ID: 27486793
    [No Abstract]   [Full Text] [Related]  

  • 25. Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial.
    Savsani E; Shaw CM; Forsberg F; Wessner CE; Lyshchik A; O'Kane P; Liu JB; Balasubramanya R; Roth CG; Naringrekar H; Keith SW; Tan A; Anton K; Bradigan K; Civan J; Schultz S; Shamimi-Noori S; Hunt S; Soulen MC; Mattrey RF; Kono Y; Eisenbrey JR
    Radiology; 2023 Oct; 309(1):e230727. PubMed ID: 37847138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance for malignant progression of LI-RADS version 2017 category 3/4 nodules using contrast-enhanced ultrasound.
    Huang H; Li CQ; He DN; Ruan SM; Li MD; Cheng MQ; Lu MD; Kuang M; Wang W; Wang Y; Chen LD
    Eur Radiol; 2023 Dec; 33(12):9336-9346. PubMed ID: 37405501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended application of subtraction arterial phase imaging in LI-RADS version 2018: a strategy to improve the diagnostic performance for hepatocellular carcinoma on gadoxetate disodium-enhanced MRI.
    Kim SS; Lee S; Bae H; Chung YE; Choi JY; Park MS; Kim MJ
    Eur Radiol; 2021 Mar; 31(3):1620-1629. PubMed ID: 32886205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inter-reader reliability of contrast-enhanced ultrasound Liver Imaging Reporting and Data System: a meta-analysis.
    Kang JH; Choi SH; Lee JS; Kim DW; Jang JK
    Abdom Radiol (NY); 2021 Oct; 46(10):4671-4681. PubMed ID: 34156509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrast-enhanced Ultrasound Identifies Patent Feeding Vessels in Transarterial Chemoembolization Patients With Residual Tumor Vascularity.
    Wessner CE; Shaw CM; Stanczak M; Forsberg F; Lyshchik A; Tan A; Eisenbrey JR
    Ultrasound Q; 2020 Sep; 36(3):218-223. PubMed ID: 32890324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma following Transarterial Chemoembolization: Is It Helpful for Tumor Response?
    Jiang T; Zhao Q; Huang M; Sun J; Tian G
    Biomed Res Int; 2018; 2018():8632069. PubMed ID: 30175147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of Contrast-Enhanced Ultrasound for Early Therapeutic Evaluation of Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization.
    Watanabe Y; Ogawa M; Kumagawa M; Hirayama M; Miura T; Matsumoto N; Nakagawara H; Yamamoto T; Moriyama M
    J Ultrasound Med; 2020 Mar; 39(3):431-440. PubMed ID: 31436341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
    Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
    Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of contrast-enhanced ultrasound and contrast-enhanced computed tomography in evaluating the treatment response to transcatheter arterial chemoembolization of hepatocellular carcinoma using modified RECIST.
    Liu M; Lin MX; Lu MD; Xu ZF; Zheng KG; Wang W; Kuang M; Zhuang WQ; Xie XY
    Eur Radiol; 2015 Aug; 25(8):2502-11. PubMed ID: 25702094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of volume perfusion computed tomography and contrast-enhanced ultrasound for assessment of therapeutic effect of transarterial chemoembolization in patients with hepatocellular carcinoma: a preliminary report.
    Kaufmann S; Schulze M; Spira D; Horger M
    Acta Radiol; 2016 Jan; 57(1):8-12. PubMed ID: 25585848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of Arterial Subtraction in Applying Liver Imaging Reporting and Data System (LI-RADS) Treatment Response Algorithm to Gadoxetic Acid-Enhanced MRI.
    Youn SY; Kim DH; Choi JI; Choi MH; Kim B; Shin YR; Oh SN; Rha SE
    Korean J Radiol; 2021 Aug; 22(8):1289-1299. PubMed ID: 34047507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra-arterial contrast-enhanced ultrasound (IA CEUS) for localization of hepatocellular carcinoma (HCC) supply during transarterial chemoembolization (TACE): a case series.
    Lekht I; Nayyar M; Luu B; Guichet PL; Ho J; Ter-Oganesyan R; Katz M; Gulati M
    Abdom Radiol (NY); 2017 May; 42(5):1400-1407. PubMed ID: 28008454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
    Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
    Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of C-arm CT for transcatheter arterial chemoembolization of hepatocellular carcinoma: diagnostic performance and predictive value for therapeutic response compared with gadoxetic acid-enhanced MRI.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    AJR Am J Roentgenol; 2013 Sep; 201(3):675-83. PubMed ID: 23971463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-life assessment of standardized contrast-enhanced ultrasound (CEUS) and CEUS algorithms (CEUS LI-RADS®/ESCULAP) in hepatic nodules in cirrhotic patients-a prospective multicenter study.
    Strobel D; Jung EM; Ziesch M; Praktiknjo M; Link A; Dietrich CF; Klinger C; Schultheiß M; Jesper D; Schellhaas B
    Eur Radiol; 2021 Oct; 31(10):7614-7625. PubMed ID: 33855588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥ 2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4.
    Kang HJ; Kim JH; Joo I; Han JK
    Abdom Radiol (NY); 2020 Jan; 45(1):55-63. PubMed ID: 31332503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.